ESTIMATING THE PREVALENCE OF RISK FACTORS FOR PROGRESSION OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS
Introduction: effective prevention of chronic kidney disease is possible on the basis of early detection of risk factors for its development, elaboration of measures for their stratification, and searching for optimal diagnostic markers.
Aim: determination of risk factors prevalence for progression of chronic kidney disease in patients with chronic glomerulonephritis.
Materials and methods. The design of the study is a cross-sectional sociological study.116 patients undergoing treatment in nephrological department of the Hospital of nephrology, internal and occupational diseases named after EM Tareev, First Moscow State Medical University named after I.M. Sechenov participated in the study of risk factors during 2014.
The criteria for inclusion in the study were diagnosed chronic glomerulonephritis, age 18-70 years. Exclusion criteria: other kidney diseases, age younger than 18 and older than 70 years.
The diagnosis of chronic glomerulonephritis was based on anamnesis of the disease, clinical (renal and extrarenall symptoms), laboratory indicators (urinary syndrome, nitrogen excretion and filtration function of the kidneys, general and biochemical blood tests), as well as results of instrumental studies (ultrasound, including echocardiography).
By analogy with the WHO-recommended STEPS method for determining risk factors for chronic non-infection diseases the study also included series of stages: interviews, anthropometric measurements and biochemical blood counts, the work was complemented by questions about specific risk factors for CKD and a large pool of objective clinical information needed for implementation the next task on risk stratification. It is possible within the framework of a survey of a patient undergoing hospital treatment.
The database was accumulated in the MS Excel program for Windows, statistical processing of the data in the study was carried out using IBM SPSS 21.0, SAS 6.0. Methods for analyzing the results: descriptive analysis.
Results: in the study group it were detected a high proportion of smokers (22.4%; 95% CI: 15.97%, 31.44%), low adherence to regular physical activity (43.1%; 95% CI: 34.97%, 53, 13%), insufficient awareness of the optimal values of blood pressure (23.9%; 95% CI: 15.8%, 36.24%) and the importance of a salt-free diet (57.8%; 95% CI: 49.43%, 67.5% %), as well as low adherence to regular surveys (56.9%; 95% CI: 48.56%, 66.65%).
Conclusion: Analyses of results of interviewing demonstrates existing potential for the implementation of preventive programs aimed at realization of modification the patient's lifestyle and forming a healthy lifestyle in patients with chronic kidney disease.
Graduate School of Health Management, First Moscow State Medical University named after I.M. Sechenov, Ministry of Health of the Russian Federation, Moscow, Russian Federation
1. Mukhin N.A. Sovremennaya nefroprotektivnaya strategiya lecheniya khronicheskikh progressiruyushchikh zabolevaniy pochek [Modern nephroprotective strategy for the treatment of chronic progressive kidney diseases]. Klinicheskaya farmakologiya i terapiya [Clinical pharmacology and therapy]. 2002. V. 11. № 2. P. 58. [in Russian].
2. Rekomendatsii VNOK i NONR «Funktsional'noe sostoyanie pochek i prognozirovanie serdechno-sosudistogo riska» [Functional state of the kidneys and predicting cardiovascular risk]. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular therapy and prevention]. 2008. №7. Attachment 3. Р. 7-37 [in Russian].
3. Smirnov A.V., Kayukov I.G., Dobronravov V.L., Esayan A.M. KhBP: dal'neyshee razvitie kontseptsii i klassifikatsii [CKD: further development of the concept and classification] // Nefrologiya [Nephrology]. 2007. № 11. P. 7-17. [in Russian].
4. Smirnov A.V., Kayukov I.G., Dobronravov V.L. Kontseptsiya faktorov riska v nefrologii: voprosy profilaktiki i lecheniya KhBP [The concept of risk factors in nephrology: issues of prevention and treatment of CKD]. Nefrologiya [Nephrology]. 2008, № 12. P. 7-13. [in Russian].
5. Shilov E.M. Organizatsiya raboty nefrologicheskoy sluzhby v RF, vzaimodeystvie s FFOMSom i MZ RF. Standarty, tarify, natsional'nye klinicheskie rekomendatsii [Organization of the work of the nephrological service in the Russian Federation, interaction with the obligatory medical insurance fund and the Ministry of Health of the Russian Federation. Standards, Tariffs, National Clinical Recommendations]. 2014. khttp://shchshchshch.-myshared.ru/slide/977929/ [in Russian].
6. Shilov E.M., Fomin V.V., Shvetsov M.Yu. Khronicheskaya bolezn' pochek [Chronic kidney disease]. Terapevticheskiy arkhiv [Therapeutic archive]. 2007, № 6. P. 75-78. [in Russian].
7. Bang H., Vupputuri S., Shoham D., Klemmer P., Falk R., Mazumdar M., Debbie G., Colindres R., Kshirsagar A. SCreening for Occult REnal Disease (SCORED). A Simple Prediction Model for Chronic Kidney Disease. Arch Intern Med. 2007. Vol.167. Р. 374-381.
8. Brück K., Stel V.S., Gambaro G., et al. CKD prevalence varies across the European general population. J Am Soc Nephrol. 2016. Vol. 27. Р. 2135–2147.
9. Brück K., Jager K.J., Dounousi E., et al. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review. Nephrol Dial Transplant. 2016. Vol. 31. Р. 680.
10. Chen N., Wang W., Huang Y., et al. Community-based study on CKD subjects and the associated risk factors. Nephrol Dial Transplant. 2009. Vol. 24. Р. 2117–2123.
11. Chien K., Lin H., Lee Ch, Hsu H., Lee Y., Chen M. A Prediction Model for the Risk of Incident Chronic Kidney Disease // The American Journal of Medicine.2010. Vol.123. Р. 836-846
12. Coresh J., Turin T.C., Matsushita K., Sang Y., Ballew S.H. et al. CKD Prognosis Consortium. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014. Vol. 311, №24. Р.2518-2531.
13. Crews D.C., Plantinga L.C., Miller E.R. et al. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States. Hypertension. 2010. Vol. 55.- Р. 1102—1109.
14. Duru O.K., Vargas R.B., Kermah D. et al. High prevalence of stage 3 chronic kidney disease in older adults despite normal serum creatinine. J. Gen. Intern. Med. 2009. Vol. 24. Р.86-92.
15. Fried L.F., Emanuele N., Zhang J.H. et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013. Vol. 369. Р. 1892–1903.
16. Grams M.E., Juraschek S.P., Selvin E. et al. Trends in the prevalence of reduced GFR in the United States: a comparison of creatinine-and cystatin C−based estimates. Am J Kidney Dis. 2013. Vol. 62- Р. 253–260.
17. Halbesma N., Jansen D., Heymans M., Stolk R., de Jong P., Gansevoort R. Development and Validation of a General Population Renal Risk Score. Clin J Am Soc Nephrol. 2011. Vol.6. Р.1731–1738.
18. Hill N.R., Fatoba S.T., Oke J.L. et al. Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS One.2016. Vol.11. e 0158765.
19. Hippisley-Cox J., Coupland C. Predicting the risk of chronic Kidney Disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores. BMC Fam Pract. 2010. P.11-49.
20. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney International Supplements. 2012, № 2. Р. 259–274.
21. Kramer H., Palmas W., Kestenbaum B. et al. Chronic kidney disease prevalence estimates among racial/ethnic groups: the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol. 2008 Vol. 3. Р. 1391–97.
22. Kshirsagar A.V., Bang H., Bomback A.S., Vupputuri S., Shoham D.A., Kern L.M., Klemmer P.J., Mazumdar M., August P.A. A simple algorithm to predict incident kidney disease. Arch Intern Med. 2008. Vol. 168, №22. Р.2466-2473.
23. Kwon K.S., Bang H., Bomback A.S., Koh D.H., Yum J.H., Lee J.H., Lee S., Park S.K., Yoo K.Y., Park S.K., Chang S.H., Lim H.S., Choi J.M., Kshirsagar A.V. A simple prediction score for kidney disease in the Korean population. Nephrology (Carlton). 2012. Vol.17, №3. Р.278-284.
24. Levin A., Tonelli M., Bonventre J., Coresh J., Donner J.A., Fogo A.B., Fox C.S., Gansevoort R.T., Heerspink H.J.L., Jardine M. et al. Global kidney health 2017 and beyond: roadmap for closing gaps in care, research, and policy. Lancet. 2017. pii: S0140-6736(17)30788-2.
25. Mann J.F., Green D., Jamerson K. et al, for the ASCEND Study Group. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010. Vol. 21. Р. 527–535.
26. Murphy D., McCulloch C.E., Lin F. et al. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med. 201. Vol. 165. Р. 473–481.
27. Parving H.H., Brenner B.M., McMurray J.J.V et al, for the ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012. Vol. 367. Р. 2204–2213.
28. Shlipak M.G., Fried L.F., Cushman M., Manolio T.A., Peterson D., Stehman-Breen C. et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005. Vol. 293. Р.1737-1745.
29. Tangri N., Grams M.E., Levey A.S., Coresh J., Appel L.J., et al. CKD Prognosis Consortium. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. JAMA. 2016. Vol. 315, №2. Р.164-174.
de Zeeuw D., Akizawa T., Audhya P. et al, for the BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013. Vol. 369. Р. 2492–2503
Bibliography link